Sage Journals: Discover world-class research

Abstract

Background:

Patients with inflammatory bowel disease (IBD) are often accompanied by a more significant burden of depression or anxiety, and approximately one-third are prescribed antidepressants. However, previous studies on the efficacy of antidepressants in IBD have shown inconsistent results.

Objectives:

To evaluate the effect of antidepressants on depression, anxiety, disease activity, and quality of life (QoL) in IBD patients.

Design:

A systematic review and meta-analysis.

Methods:

We searched MEDLINE via Ovid, EMBASE via Ovid, the Cochrane Library, CINAHL, PsycINFO, Chinese CBM Database, China National Knowledge Infrastructure, VIP, and Wanfang Database from inception to 13th July 2022 without language restrictions.

Results:

In all, 13 studies containing 884 individuals were included. Compared with the control group, antidepressants were superior in reducing depression scores [standardized mean difference (SMD) = −0.791; 95% confidence interval (CI): −1.009 to −0.572; p < 0.001], anxiety scores (SMD = −0.877; 95% CI: −1.203 to −0.552; p < 0.001), and disease activity scores (SMD = −0.323; 95% CI: −0.500 to −0.145; p < 0.001). Antidepressants had a positive effect in reaching clinical remission [risk ratio (RR) = 1.383; 95% CI: 1.176–1.626; p < 0.001]. Higher physical QoL (SMD = 0.578; 95% CI: 0.025–1.130; p = 0.040), social QoL (SMD = 0.626; 95% CI: 0.073–1.180; p = 0.027), and Inflammatory Bowel Disease Questionnaire (SMD = 1.111; 95% CI: 0.710–1.512; p < 0.001) were found in the experimental group. No significant differences were observed in clinical response (RR = 1.014; 95% CI: 0.847–1.214; p = 0.881), psychological QoL (SMD = 0.399; 95% CI: −0.147 to 0.944; p = 0.152), and environmental QoL (SMD = 0.211; 95% CI: −0.331 to 0.753; p = 0.446).

Conclusion:

Antidepressants are effective for ameliorating depression, anxiety, disease activity, and QoL in IBD patients. Due to most studies having a small sample size, further well-designed studies are required.

Keywords

antidepressants inflammatory bowel disease meta-analysis

Introduction

Inflammatory bowel disease (IBD) is a chronic disorder that comprises ulcerative colitis (UC) and Crohn’s disease (CD), the former affecting only the colon, and the latter can involve any part of the gastrointestinal tract.¹ IBD is a lifelong disease characterized by repeated remissions and relapses with no cure. The clinical manifestations of IBD are diverse, and typical symptoms include abdominal pain, weight loss, diarrhea, etc.² IBD has a significant impact on the quality of life (QoL) of patients. A systematic review confirmed that compared with healthy individuals, the QoL of patients with IBD was poorer.³ Further studies found that the QoL of IBD was worse during active disease.⁴ In addition, IBD treated with steroids had lower QoL than that of non-users,^5,6 which was because steroids use was associated with increased disease activity,⁷ and side effects of steroids could affect QoL, such as moon face, acne, weight gain, etc.⁸ A recent review reported the overall prevalence of IBD surpasses 0.3%.⁹ In the United States, the prevalence of IBD in children and adults in 2016 is 77 and 478.4 per 100,000 people, respectively.¹⁰ The prevalence of IBD is estimated to be 970 per 100,000 population in the United Kingdom and 725 per 100,000 population in Canada.^11,12 In South Korea, the prevalence of UC and CD between 2009 and 2016 has increased from 41.4 and 16.0 to 66.0 and 29.6 per 100,000 population, respectively.¹³

IBD is often accompanied by psychiatric disorders encompassing depression and anxiety.^14,15 The incidence of depression is significantly higher in IBD patients than in non-IBD patients.¹⁶ Two recent reviews revealed the pooled prevalence of depression in IBD was 21.2%¹⁷ and 25.6%,¹⁸ and the pooled prevalence of anxiety was 35.1%¹⁷ and 32.1%,¹⁸ respectively. Depression or anxiety symptoms negatively correlate with the QoL in patients with IBD.^19,20 Meanwhile, IBD with depression or anxiety has a significantly higher disease burden, with some studies reporting higher rates of steroid or biologic use, hospitalization, surgery, relapse, and use of emergency resources in such populations.^21–23 Alexakis et al.²⁴ conducted a systematic review and meta-analysis and found no association between comorbid depression and worsening IBD disease course. However, a recent meta-analysis on this subject, which included more original studies with longer follow-up, suggested that symptoms of depression or anxiety were significantly related to worsening IBD disease course.²⁵

Approximately 10–30% of patients with IBD have been treated with antidepressants.²⁶ However, there are no standard strategies for IBD patients with depression or anxiety. Most studies have shown that IBD benefits from antidepressants, whereas a small randomized controlled trial (RCT) found no benefit of fluoxetine on the condition or mental health of IBD patients.²⁷ A recent review by Mikocka-Walus in 2019 exploring the efficacy of antidepressants in patients with IBD failed to reach definitive conclusions due to the small sample size and the inclusion of non-RCTs (NRCT).²⁸ In this study, we synthesized new data to systematically investigate the effect of antidepressants on depression, anxiety, disease activity, and QoL in IBD population.

Methods

Search strategy

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to develop our search strategy.²⁹ Searches of MEDLINE via Ovid, EMBASE via Ovid, the Cochrane Library, CINAHL, PsycINFO, Chinese CBM Database, China National Knowledge Infrastructure, VIP, and Wanfang Database from inception to 13th July 2022 were conducted, using the following terms: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, depression, depressive disorder, anxiety, anxiety disorder, and antidepressants. To get more original research, we did not restrict languages. Search strategies in every online database are introduced in the Supplemental Material. This study was not registered on PROSPERO, but we will complete the corresponding registration in future studies.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) all published RCTs; (2) individuals were diagnosed with IBD, including CD and UC, according to standard practice; (3) antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine reuptake inhibitors, norepinephrine–dopamine reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, serotonin antagonist and reuptake inhibitors, monoamine oxidase Inhibitor, tricyclics, and other unclassified antidepressants, were used in the intervention group; (4) outcomes were continuous outcomes of depression, anxiety, disease activity, QoL or dichotomous outcomes of clinical remission or clinical response.

The exclusion criteria were as follows: (1) animal experiments; (2) observational studies, retrospective studies, case reports, letters, reviews, and meta-analysis; (3) Chinese medicine treatment for IBD; and (4) no full text, or insufficient data for calculation.

Selection studies

Two investigators independently screened studies that met pre-determined inclusion and exclusion criteria. Discrepancies were resolved by discussion, and if required, the third author was asked to arbitrate.

Data extraction

Two reviewers conducted data extractions and extracted the following data if mentioned in the original literature: (1) basic information: first author name, publication year, country, sample size, interventions of treatment and control groups, trial duration; (2) demographic characteristics: age, gender, type of IBD, course of illness, and severity; (3) results: psychological assessment (depression and anxiety), disease activity (disease activity score, laboratory test results), clinical efficacy (clinical remission and clinical response defined by the respective article authors), and QoL. For each trial, we extracted data at the final time of follow-up. For missing or unclear information, we contacted the investigators to obtain relevant information.

Quality assessment

The risk of bias for each study was assessed by two independent authors according to the Cochrane risk of bias tool, covering six domains.³⁰ Each item was categorized as ‘Low risk,’ ‘High risk’, or ‘Unclear risk’. Any disagreement was discussed, reaching a consensus.

Statistical analysis

All analyses were performed using RevMan 5.4 and STATA. 17.0. Standardized mean difference (SMD) and 95% confidence interval (CI) were used to characterize continuous outcomes. Risk ratio (RR) and 95% CI were used to represent discontinuous outcomes. We calculated Cochrane chi² and I² to evaluate the heterogeneity across studies. A p value of less than 0.10 was defined as significant heterogeneity. Thresholds for the interpretation of the I² statistic are as follows: 0–40%, indicating that heterogeneity may not be important; 30–60% may represent moderate heterogeneity; 50–90% may represent substantial heterogeneity; and 75–100%, representing considerable heterogeneity.³¹ If p < 0.10 or I² > 40%, we considered the heterogeneity significant and conducted a meta-analysis using a random-effects model. The fixed-effect model was applied if p > 0.10 or I² < 40%. We generated a funnel plot to test publication bias and performed Begg’s and Egger’s tests. A sensitivity analysis was executed to check the robustness of the summarized results. In addition, subgroup analysis and meta-regression were conducted to explore the possible source of heterogeneity, including mean age, gender ratio, type of antidepressants, and length of treatment.

Results

Literature search

In all, 1556 potentially eligible studies were identified. After removing duplicates, we scanned the titles and abstracts of 1171 articles. Articles excluded were systematic reviews, non-RCTs, not IBD or UC or CD related, or without antidepressant treatment. In all, 46 papers were read in full. We contacted the authors for articles with insufficient data, and only Liang³² responded. In total, 33 papers were excluded for different reasons. In all, 18 studies included combination therapy without separate data on antidepressant efficacy, five were not RCTs, four lacked appropriate control measures, three were clinical trials with overlapping data from published literature, and three did not explore the effect of antidepressants on depression or anxiety symptoms (Figure 1). References of qualified articles were also read in full. No additional citations were added. In all, 13 articles were finally included.^27,32–43

Figure 1.

Flow diagram of study selection.

Study characteristics

A total of 884 individuals were recruited. There were 446 participants in the experimental group and 438 in the control group. The sample sizes ranged from 18 to 126. One study was from Australia²⁷ and one from Iran,⁴² and the others were from China.^32–41,43 All eligible articles reported the mean age and sex ratio. Most RCTs enrolled patients with UC,^33–41,43 only Mikocka-Walus et al.²⁷ included patients with CD, and Liang et al.³² and Daghaghzadeh et al.⁴² recruited patients with UC or CD. The mental health of the patients recruited in each study was disparate, with six trials only recruiting IBD with depression,^{33,35,37–39,41} while four enrolled IBD with depression or anxiety,^32,34,40,43 and three studies had no requirements on the psychological states of IBD patients included.^27,36,42 Follow-up durations ranged from 2 weeks to 12 months. Interventions differed between studies. Sertraline was used in six experiments,^{33,35,37–39,41} paroxetine was used in four experiments,^34,36,40,43 and venlafaxine,³² fluoxetine,²⁷ and duloxetine⁴² were used in one experiment each.

Assessment tools for depression and anxiety varied among trials. Five studies used Hamilton Depression Scale to measure the severity of depression,^{34,36,38,40,43} five utilized the Self-Rating Depression Scale,^{33,35,37,39,41} and three used Hospital Anxiety and Depression Scale-Depression (HADS-D).^27,32,42 Meanwhile, the Hamilton Anxiety Scale was employed to assess the severity of anxiety in four RCTs,^34,36,40,43 and HADS-Anxiety was applied in three trials.^27,32,42 Regarding the secondary outcome measures, seven articles reported disease activity scores, of which four used the Ulcerative Colitis Activity Index,^35,37,38,41 one used the Lichtiger Colitis Activity Index,⁴² one used the Clinical Activity Index,⁴³ and one paper used CDAI and Mayo score, respectively.³² Other metrics for disease activity assessment involved erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), etc. The definition of clinical remission and clinical response was inconsistent. Clinical remission was used to examine clinical efficacy in 10 experiments,^27,33–41 and 9 of them also reported clinical response.^33–41 The Inflammatory Bowel Disease Questionnaire (IBDQ), physical QoL, psychological QoL, social QoL, and environmental QoL were applied to measure the QoL. Characteristics of included trials are displayed in Table 1.

Table 1.

Characteristics of the included studies.

	Inclusion criteria		Country	Sample size	Gender ratio	Mean age (years)	Interventions	Control methods	Length of treatment	Outcomes
	Disease type	Psychological status	Country	Sample size	Gender ratio	Mean age (years)	Interventions	Control methods	Length of treatment	Outcomes
Liang et al.³²	IBD	Depression/anxiety (HADS-D ⩾ 8/HADS-A ⩾ 8)	China	40	1.25	40.0	Venlafaxine + ST	ST + placebo	6 months	Psychological assessment: HADS Disease activity: Mayo score, CDAI, ESR, CRP, TNF-α, IL-10 Quality of life: IBDQ
Gong³³	UC	Depression	China	42	1.00	50.6	Sertraline + ST	ST	2 weeks	Psychological assessment: SDS Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as basically disappearance of clinical symptoms, mild inflammation under endoscopy)
Shen et al.³⁴	UC	Depression/anxiety (HAMD-17:7–24/HAMA: 14–29)	China	126	1.07	71.7	Paroxetine + ST	ST	8 weeks	Psychological assessment: HAMD-17, HAMA Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as basically disappearance of clinical symptoms, mild inflammation under endoscopy)
Feng et al.³⁵	UC	Depression (SDS: 53–70)	China	118	1.15	30.1	Sertraline + ST	ST	12 weeks	Psychological assessment: SDS Disease activity: UCAI Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as basically disappearance of clinical symptoms, inflammation under endoscopy)
Mikocka-Walus et al.²⁷	CD	NA	Australian	18	1.17	37.4	Fluoxetine + ST	ST + placebo	12 months	Psychological assessment: HADS Disease activity: CDAI Clinical efficacy: clinical remission (defined as CDAI < 150 points) Quality of life: physical QOL, psychological QOL, social QOL, environmental QOL
Tao et al.³⁶	UC	NA	China	74	2.22	69.1	Paroxetine + ST	ST	2 months	Psychological assessment: HAMD, HAMA Clinical efficacy: clinical remission (defined as a decrease in the DAI ⩾ 50% from baseline/DAI ⩽ 2 points), clinical response (defined as a DAI score reduction of ⩾1 point)
Duan³⁷	UC	Depression (SDS ⩾ 53)	China	98	1.28	41.6	Sertraline + ST	ST	12 weeks	Psychological assessment: SDS Diseases activity: UCAI Clinical efficacy: clinical remission (defined as basically disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as improvement in clinical symptoms, inflammation under endoscopy)
Zhang et al.³⁸	UC	Depression	China	81	1.38	38.2	Sertraline + ST	ST	12 weeks	Psychological assessment: HAMD Disease activity: UCAI Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as disappearance of clinical symptoms, no positive findings under endoscopy)
Shi³⁹	UC	Depression	China	70	1.19	43.4	Sertraline + ST	ST	12 weeks	Psychological assessment: SDS Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as improvement of clinical symptoms, no positive findings under endoscopy)
Li et al.⁴⁰	UC	Depression/anxiety (HAMD: 17–24/HAMA: 7–29)	China	72	0.90	63.6	Paroxetine + ST	ST	8 weeks	Psychological assessment: HAMD, HAMA Clinical efficacy: clinical remission (defined as a partial Mayo score of ⩽3 points), clinical response (defined as a partial Mayo score of 3–5points) Quality of life: IBDQ
Zhou et al.⁴¹	UC	Depression (SDS > 53)	China	80	1.29	36.1	Sertraline + ST	ST	12 weeks	Psychological assessment: SDS Disease activity: UCAI Clinical efficacy: clinical remission (defined as disappearance of clinical symptoms, no positive findings under endoscopy), clinical response (defined as basically disappearance of clinical symptoms, no positive findings under endoscopy)
Daghaghzadeh et al.⁴²	IBD	NA	Iran	35	1.19	38.0	Duloxetine + ST	ST + placebo	12 weeks	Psychological assessment: HADS Disease activity: LCAI Quality of life: physical QOL, psychological QOL, social QOL, environmental QOL
Song et al.⁴³	UC	Depression or anxiety (HAMD ⩾ 17/HAMA ⩾14)	China	30	1.50	40.3	Paroxetine + ST	ST	2 months	Psychological assessment: HAMD, HAMA Disease activity: CAI

IBD, inflammatory bowel disease; HADS-D, depression subscale of the Hospital Anxiety and Depression Scale; HADS-A, anxiety subscale of the Hospital Anxiety and Depression Scale; ST, standard therapy; HASD, Hospital Anxiety and Depression Scale; CDAI, Crohn’s Disease Activity Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; TNF-a, tumor necrosis factor α; IL-10, interleukin 10; IBDQ, Inflammatory Bowel Disease Questionnaire; UC, ulcerative colitis; NA, no available; SDS, Self-rating depression scale; HAMD-17, 17-Item Hamilton Rating Scale for Depression; HAMA, Hamilton Anxiety Scale; UCAI, ulcerative colitis activity index; HAMD, Hamilton Depression Scale; CD, Crohn’s disease; QOL, quality of life; LCAI, Lichtiger Colitis Activity Index; DAI, disease activity index; CAI, clinical activity index.

Risk of bias

The appraisal results of the risk of bias for included trials are presented in Figures 2 and 3.

Figure 2.

Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.

Figure 3.

Risk of bias summary: review authors’ judgments about each risk of bias item for each included study.

Primary outcomes

Depression

All RCTs completed assessments of depression. Since I² = 56.9% (p = 0.006), we reported random-effect models. Significant reductions in depressive scores were observed with the use of antidepressants in IBD patients (Figure 4(a); SMD = −0.791; 95% CI: −1.009 to −0.572; p < 0.001). The funnel plot showed no publication bias (Figure 4(b)). The result was consistent with Begg’s (p = 0.669) and Egger’s tests (p = 0.554). A sensitivity analysis was performed by excluding included articles one by one, indicating that the result was consistent and without fluctuation (Figure 4(c)). Subgroup analyses based on mean age, sex ratio, type of antidepressants, and length of treatment found that the intervention did not affect depression in the SNRI subgroup and that heterogeneity between studies could be explained by the length of treatment (Table 2). The meta-regression also demonstrated that the length of treatment was associated with heterogeneity (Table 3).

Figure 4.

Comparison of depression symptoms: (a) forest plot, (b) funnel plots, and (c) sensitivity analysis.

Table 2.

Subgroup analysis for depression symptoms.

Confounders	N	Meta-analysis			Heterogeneity
		Pooled SMD	95% CI	p Value	I² (%)	p Value
Mean age (years)
⩽40	7	−0.620	−0.831 to −0.409	<0.001	9.0	0.360
>40	6	−0.987	−1.328 to −0.646	<0.001	66.0	0.012
Gender ratio
⩽1	2	−1.254	−1.657 to −0.851	<0.001	0.0	0.611
>1	11	−0.717	−0.945 to −0.489	<0.001	55.0	0.014
Types of antidepressants
SSRI	11	−0.850	−1.083 to −0.617	<0.001	58.3	0.008
SNRI	2	−0.375	−0.833 to 0.083	0.108	0.0	0.807
Length of treatment
⩽8 weeks	3	−1.292	−1.571 to −1.013	<0.001	0.0	0.851
>8 weeks	10	−0.643	−0.834 to −0.453	<0.001	26.1	0.203

CI, confidence interval; N, number of trials; SMD, standardized mean difference;SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.

Table 3.

Meta-regression analysis for depression symptoms.

Confounders	Meta-regression
	Coefficient	95% CI	p Value
Mean age (years)	−0.378	−0.831 to 0.074	0.093
Gender ratio	0.524	−0.133 to 1.180	0.107
Types of antidepressants	0.474	−0.246 to 1.193	0.175
Length of treatment	0.641	0.255 to 1.028	0.004

CI, confidence interval.

Anxiety

Seven studies discussed the impact of antidepressants in reducing anxiety scores in patients with IBD. We pooled data from 395 participants using a random-effect model (Figure 5(a); I² = 53.6%; p = 0.044), indicating that antidepressants did ease anxiety symptoms (Figure 5(a); SMD = −0.877; 95% CI: −1.203 to −0.552; p < 0.001). Publication bias and meta-regression were not assessed due to fewer than 10 articles.^44,45 Sensitivity analysis confirmed the robustness of the results (Figure 5(b)). Subgroup analysis indicated that the length of treatment might be a contributing factor to heterogeneity. There was no evidence that interventions differed in efficacy across subgroups of mean age and type of antidepressant (Table 4).

Figure 5.

Comparison of anxiety symptoms: (a) forest plot and (b) sensitivity analysis.

Table 4.

Subgroup analysis for anxiety symptoms.

Confounders	N	Meta-analysis			Heterogeneity
		Pooled SMD	95% CI	p Value	I² (%)	p Value
Mean age (years)
⩽40	3	−0.448	−0.862 to −0.034	0.034	0.0	0.764
>40	4	−1.112	−1.445 to −0.780	<0.001	41.5	0.162
Type of antidepressants
SSRI	5	−1.012	−1.382 to −0.643	<0.001	53.1	0.074
SNRI	2	−0.509	−0.970 to −0.047	0.031	0.0	0.648
Length of treatment
⩽8 weeks	2	−1.282	−1.589 to −0.976	<0.001	0.0	0.392
>8 weeks	5	−0.635	−0.924 to −0.347	<0.001	0.0	0.536

CI, confidence interval; N, number of trials; SMD, standardized mean difference; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.

Secondary outcomes

Disease activity scores

Eight studies assessed the ability of antidepressants on disease activity using correlation scales. Antidepressants could significantly alleviate the severity of the disease (Figure 6(a); SMD = −0.323; 95% CI: −0.500 to −0.145; p < 0.001), with low heterogeneity between studies (Figure 6(a); I² = 22.7%; p = 0.241). Sensitivity analyses were conducted, and no obvious changes were observed after each study was sequentially omitted (Figure 6(b)). We noted no significant difference in disease activity scores in the subgroup with a mean age > 40 (Supplemental Table 1).

Figure 6.

Comparison of disease activity scores: (a) forest plot and (b) sensitivity analysis.

Clinical remission

Ten RCTs reported data for the effect of antidepressants on clinical remission. The pooled results revealed that antidepressants were effective in the induction of clinical remission (Figure 7(a); RR = 1.383; 95% CI: 1.176–1.626; p < 0.001; I² = 34.7%). Visual inspection of the funnel plot appears to be asymmetric (Figure 7(b)). However, Begg’s (p = 0.592) and Egger’s (p = 0.270) tests demonstrated that publication bias was not significant. Sensitivity analysis showed that the results were stable (Figure 7(c)). Subgroup analysis according to mean age, length of treatment, and gender ratio showed no effect of antidepressants on clinical remission in subgroups with a gender ratio of ⩽1 or treatment duration of ⩽8 weeks (Supplemental Table 2). Regression analysis also did not hint at the source of heterogeneity (Supplemental Table 3).

Figure 7.

Comparison of clinical remission: (a) forest plot, (b) funnel plots, and (c) sensitivity analysis.

Clinical response

We pooled data from nine manuscripts and found no benefit from the intervention in inducing a clinical response (Figure 8(a); RR = 1.014; 95% CI: 0.847−1.214; p = 0.881; I² = 0%). Sensitivity analysis confirmed the stability of the results (Figure 8(b)). In terms of clinical response, none of the subgroup analyses indicated an advantage of the intervention (Supplemental Table 4).

Figure 8.

Comparison of clinical response: (a) forest plot and (b) sensitivity analysis.

Quality of life

Two articles documented data on physical QoL, psychological QoL, social QoL, and environmental QoL. We only observed benefits in physical QoL (Figure 9(a); SMD = 0.578; 95% CI: 0.025–1.130; p = 0.040; I² = 0%), and social QoL scores (Figure 9(c); SMD = 0.626; 95% CI: 0.073–1.180; p = 0.027; I² = 0%). No significant change in psychological QoL (Figure 9(b); SMD = 0.399; 95% CI: −0.147 to 0.944; p = 0.152; I² = 0%) and environmental QoL (Figure 9(d); SMD = 0.211; 95% CI: −0.331 to 0.753; p = 0.446; I² = 0%) scores.

Figure 9.

Comparison of QoL: (a) physical QoL, (b) psychological QoL, (c) social QoL, (d) environmental QoL, and (e) IBDQ.

Two other articles used the IBDQ as a questionnaire to assess health-related QoL in IBD patients. Compared with the control group, the IBDQ score of the experimental group was significantly higher (Figure 9(e); SMD = 1.111; 95% CI: 0.710–1.512; p < 0.001; I² = 28.2%).

All secondary outcomes were analyzed using a fixed-effects model. Some other secondary outcomes, such as ESR, CRP, etc., were mentioned in only one study, thus, we did not perform a meta-analysis.

Discussion

The results suggested that using antidepressants in IBD patients could mitigate depression, anxiety, and disease activity, and improve physical QoL, social QoL and IBDQ scores. As for clinical efficacy, antidepressants were effective only in the induction of clinical remission not in clinical response. Given that clinical remission has far higher heterogeneity than clinical response, this finding needs to be interpreted with caution.

Sensitivity analysis proved the robustness and stability of our results, although significant heterogeneity was observed when analyzing changes in depression and anxiety scores. Further subgroup analysis suggested that intervention duration might be a source of heterogeneity. The WFSBP guidelines recommend 2–4 weeks to evaluate the early efficacy of antidepressants, and at least 8–10 weeks to achieve maximum symptom reduction.⁴⁶ However, a retrospective population-based study in the United Kingdom found that 34% of IBD discontinue antidepressants within 28 days, which may be because of poor tolerability.⁴⁷ We, therefore, selected the minimum treatment duration, 8 weeks, as the basis for the subgroup analyses. Antidepressants were effective in both subgroups, it was interesting to note that compared with IBD patients treated for >8 weeks, patients treated for ⩽8 weeks benefited more from antidepressants in alleviating depression and anxiety symptoms. This result might arise from some studies with treatment duration >8 weeks that did not recruit IBD with depression or anxiety. Subgroup analyses showed that SNRI improved depressive symptoms in IBD patients, but the difference was not significant. Considering that the sample size of the subgroup was small may not be able to check out the difference between the control and experimental groups. No significant improvement in disease activity scores was observed between the experimental and control groups, with a mean age >40. Neither sex ratio ⩽1 nor treatment duration ⩽8 weeks of IBD had clinical remission benefits from antidepressant use. In addition to the small sample size, these subgroups were highly heterogeneous, and we also needed to interpret these results with caution.

A previous systemic review and meta-analysis, limited by sample size and the inclusion of NRCTs, had cautiously recommended that antidepressants improve depressive and anxiety symptoms in IBD patients.²⁸ In this paper, all the studies included were RCTs, and the quality of evidence may be higher. In addition, meta-analysis is a statistical method that can combine results from different but thematically similar studies. In addition to the relevant English databases, the Chinese databases were also searched in this paper, and articles in Chinese that met inclusion and exclusion criteria were included. Furthermore, every effort was made to contact the authors of potentially eligible research for which data of interest were not available in the published manuscript, and in the end, only the authors of one study published in 2022 responded.³² We included a total of 13 eligible articles, nine more than included in the Cochrane review, and four times more people than included in the Cochrane review.²⁸ Finally, subgroup analysis was performed to explore the potential sources of heterogeneity, the efficacy of antidepressants for IBD with different clinical features, and the effect of different antidepressants in IBD. This meta-analysis is helpful to standardize the use of antidepressants in patients with IBD.

Antidepressants work by compensating for the reduction or absence of neurotransmitters.⁴⁸ Previous studies have found lower levels of serotonin and norepinephrine in the inflamed mucosa of patients with IBD than in healthy controls.^49,50 It is hypothesized that the SSRI- and SNRI-induced increase in serotonin and norepinephrine is the underlying reason for the efficacy of antidepressants in IBD. Moreover, a growing number of articles have reported that antidepressants have anti-inflammatory properties.^51–53 In animal models of IBD, antidepressants reduced the serum concentrations of interleukin 1β and TNF, attenuated intestinal myeloperoxidase levels, and improved intestinal inflammation,^54,55 possibly through modulation of nuclear factor-κB and nitric oxide (NO) signaling.⁵⁶

This review also has some limitations. First, some studies we included may have enrolled patients with IBD who had previously used antidepressants or who had other psychiatric conditions. Considering that antidepressants have a significant time-course relationship⁵⁷ and can also improve symptoms of other psychiatric disorders,^58–60 our findings may be exaggerated. Second, most of the studies were conducted in Asia, which means that our results may not be generalizable to all IBD populations. Third, the volume of the available literature is small, and the power to assess the effectiveness of antidepressants in the IBD population may be insufficient. Fourth, the evidence quality was low, with most of the literature did not specify the implementation of randomization and blinding. This limits the persuasiveness of our results. Ultimately, IBD is a recurrent disease, and we think it is essential to explore the long-term effects of antidepressants in IBD patients. Masaki Kato et al. found that in patients with severe depression, antidepressant treatment of <6 months after remission was associated with increased risk of relapse of depression.⁶¹ Unfortunately, because none of the included studies provided data on follow-up after antidepressant discontinuation, we cannot make a judgment.

In the future, high-quality, large-sample, multicenter RCTs with adequate follow-up periods are needed to understand the effects of antidepressants on individuals with IBD. More objective inflammatory indicators, like CRP and ESR, are also required.

Conclusion

Our study demonstrated that antidepressants improved outcomes in IBD patients, including comorbidities of depression and anxiety, disease activity, clinical remission, physical and social QoL, and IBDQ. However, antidepressants did not show advantages in terms of clinical response, psychological QoL, and environmental QoL. In conclusion, antidepressants are a potential adjunctive therapy for IBD. Considering that most of these studies have a very small sample size (<100 in most) and the low quality of some studies, high-quality studies are warranted in the future.

Supplemental Material

sj-docx-1-tag-10.1177_17562848231155022 – Supplemental material for Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis

Supplemental material, sj-docx-1-tag-10.1177_17562848231155022 for Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis by Liangfang Wang, Chang Liang, Pingrun Chen, Yubin Cao and Yan Zhang in Therapeutic Advances in Gastroenterology

Footnotes

Acknowledgements

The authors are grateful to Sichuan University for access to MEDLINE, EMBASE, Chinese CBM Database, China National Knowledge Infrastructure, VIP, and Wanfang Database.

Declarations

ORCID iDs

Liangfang Wang

Pingrun Chen

Yan Zhang

Supplemental material

Supplemental material for this article is available online.

References

Okobi

Udoete

Fasehun

, et al. A review of four practice guidelines of inflammatory bowel disease. Cureus 2021; 13: e16859.

Nakase

Uchino

Shinzaki

, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021; 56: 489–526.

Knowles

Graff

Wilding

, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm Bowel Dis 2018; 24: 742–751.

Knowles

Keefer

Wilding

, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis 2018; 24: 966–976.

Bernklev

Jahnsen

Schulz

, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005; 17: 1037–1045.

Haapamäki

Turunen

Roine

, et al. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual Life Res 2009; 18: 961–969.

Faubion

Jr Loftus

Jr Harmsen

, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255–260.

Irvine

EJ.

Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008; 14: 554–565.

Shi

Hamidi

, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778.

10.

Manne

Treem

, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis 2020; 26: 619–625.

11.

King

Reulen

Thomas

, et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000–2018. Aliment Pharmacol Ther 2020; 51: 922–934.

12.

Coward

Clement

Benchimol

, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019; 156: 1345–1353.e4.

13.

Kwak

Cha

Lee

, et al. Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J Gastroenterol Hepatol 2019; 34: 1018–1026.

14.

Bernstein

Hitchon

Walld

, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis 2019; 25: 360–368.

15.

Chen

, et al. Depression and anxiety disorders in patients with inflammatory bowel disease. Front Psychiatry 2021; 12: 714057.

16.

Blackwell

Saxena

Alexakis

, et al. DOP85 rising depression and antidepressant use amongst inflammatory bowel disease patients. J Crohns Colitis 2019; 13: S081–S082.

17.

Neuendorf

Harding

Stello

, et al. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J Psychosom Res 2016; 87: 70–80.

18.

Barberio

Zamani

Black

, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6: 359–370.

19.

Zhang

Hewett

Hemming

, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1732–1739.

20.

Yamamoto-Furusho

Bozada Gutiérrez

Sarmiento-Aguilar

, et al. Depression and anxiety disorders impact in the quality of life of patients with inflammatory bowel disease. Psychiatry J 2021; 2021: 5540786.

21.

Navabi

Gorrepati

Yadav

, et al. Influences and impact of anxiety and depression in the setting of inflammatory bowel disease. Inflamm Bowel Dis 2018; 24: 2303–2308.

22.

Dubinsky

Dotan

Rubin

, et al. Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev Gastroenterol Hepatol 2021; 15: 985–997.

23.

Mikocka-Walus

Pittet

Rossel

, et al. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14: 829–835.e1.

24.

Alexakis

Kumar

Saxena

, et al. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46: 225–235.

25.

Fairbrass

Lovatt

Barberio

, et al. Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut 2022; 71: 1773–1780.

26.

Macer

BJD

Prady

Mikocka-Walus

Antidepressants in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2017; 23: 534–550.

27.

Mikocka-Walus

Hughes

Bampton

, et al. Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn’s disease: a pilot randomized placebo-controlled trial. J Crohn Colitis 2017; 11: 509–514.

28.

Mikocka-Walus

Prady

Pollok

, et al. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev 2019; 4: CD012680.

29.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.

30.

Higgins

Altman

Gøtzsche

, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

31.

Deeks

Higgins

JPT

Altman

. Analysing data and undertaking meta-analyses. In: Higgins

JPT

Thomas

Chandler

, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook

32.

Liang

Chen

Tang

, et al. Venlafaxine as an adjuvant therapy for inflammatory bowel disease patients with anxious and depressive symptoms: a randomized controlled trial. Front Psychiatry 2022; 13: 880058.

33.

Gong

ZC.

Effect of sertraline hydrochloride combined with mesalazine in the treatment of ulcerative colitis patients with depression. Wuhan, Hubei: Wuhan University, Women’s Health Research, 2020, pp.31–52.

34.

Shen

Kang

, et al. Clinical study of paroxetine combined with mesalazine in the treatment of elderly ulcerative colitis patients with anxiety and depression. J Ningxia Med Univ 2018; 40: 20190805.

35.

Feng

HD.

Study on the application of sertraline hydrochloride in the treatment of ulcerative colitis patients with depression. Ningxia Med J 2017; 39: 20170605.

36.

Tao

Sun

, et al. Effect of paroxetine combined with conventional therapy in the treatment of elderly ulcerative colitis patients. Mod Digest Intervention 2016; 21: 20170323.

37.

Duan

CC.

Clinical study of sertraline hydrochloride combined with mesalazine in the treatment of ulcerative colitis patients with depression. Chronic Pathematol J 2016; 17: 560–562.

38.

Zhang

Shen

Zhang

, et al. Clinical study of sertraline hydrochloride combined with mesalazine in the treatment of ulcerative colitis patients with depressive symptoms. Chinese J Mod Drug Appl 2016; 10: 20170128.

39.

Shi

XJ.

Efficacy evaluation of sertraline hydrochloride combined with mesalazine in the treatment of ulcerative colitis patients with depression. Chinese J Clin Ration Drug Use 2016; 9: 46–47.

40.

YR.

Paroxetine hydrochloride as adjuvant therapy for 40 cases of elderly ulcerative colitis patients with anxiety or depression. Her Med 2015; 34: 20160204.

41.

Zhou

JJ.

Effect of sertraline hydrochloride in the treatment of ulcerative colitis patients with depression. Chinese J Digest 2015; 35: 20161130.

42.

Daghaghzadeh

Naji

Afshar

, et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. J Res Med Sci 2015; 20: 595–601.

43.

Song

Zhan

Efficacy assessment of paroxetine in the treatment of patients with mild-moderate ulcerative colitis accompanied with anxiety or depression. Chinese J Gastroenterol Hepatol 2012; 21: 20120830.

44.

Egger

Smith

Schneider

, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

45.

Schmid

Stark

Berlin

, et al. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683–697.

46.

Bauer

Severus

Möller

, et al. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract 2017; 21: 166–176.

47.

Jayasooriya

Blackwell

Saxena

, et al. Antidepressant medication use in inflammatory bowel disease: a nationally representative population-based study. Aliment Pharmacol Ther 2022; 55: 1330–1341.

48.

Gaur

Sharma

. Antidepressants: mechanism of action, toxicity and possible amelioration. J Appl Biotechnol Bioeng 2017; 3: 437–448.

49.

Magro

Vieira-Coelho

Fraga

, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 2002; 47: 216–224.

50.

Coates

Mahoney

Linden

, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657–1664.

51.

Kubera

Lin

Kenis

, et al. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199–206.

52.

Diamond

Kelly

Connor

TJ.

Antidepressants suppress production of the Th1 cytokine interferon-γ, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006; 16: 481–490.

53.

Ohgi

Futamura

Kikuchi

, et al. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2013; 103: 853–859.

54.

Varghese

Verdú

Bercik

, et al. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology 2006; 130: 1743–1753.

55.

Guemei

El Din

Baraka

, et al. Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats? J Pharmacol Exp Ther 2008; 327: 846–850.

56.

Rahimi

Shiri

Razmi

Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: a hypothesis. World J Gastrointest Pharmacol Ther 2012; 3: 83–85.

57.

Cheng

Huang

, et al. Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. Int J Neuropsychopharmacol 2020; 23: 76–87.

58.

Helfer

Samara

Huhn

, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173: 876–886.

59.

Bighelli

Castellazzi

Cipriani

, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2018; 4: CD010676.

60.

de Moraes Costa

Ziegelmann

Zanatta

, et al. Efficacy, acceptability, and tolerability of antidepressants for sleep quality disturbances in post-traumatic stress disorder: a systematic review and network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2022; 117: 110557.

61.

Kato

Hori

Inoue

, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 2021; 26: 118–133.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

Effect of antidepressants on psychological comorbidities,disease activity,and quality of life in inflammatory bowel disease: a systematic review and meta-analysis

Abstract

Background:

Objectives:

Design:

Methods:

Results:

Conclusion:

Keywords

Introduction

Methods

Search strategy

Inclusion and exclusion criteria

Selection studies

Data extraction

Quality assessment

Statistical analysis

Results

Literature search

Study characteristics

Risk of bias

Primary outcomes

Depression

Anxiety

Secondary outcomes

Disease activity scores

Clinical remission

Clinical response

Quality of life

Discussion

Conclusion

Supplemental Material

sj-docx-1-tag-10.1177_17562848231155022 – Supplemental material for Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis

Footnotes

Acknowledgements

Declarations

ORCID iDs

Supplemental material

References

Supplementary Material